A Phase 1, Open-label Study of SNX‑5422 Added to Ibrutinib in Chronic Lymphocytic Leukemia Subjects With Residual Disease
Phase of Trial: Phase I
Latest Information Update: 19 Oct 2017
At a glance
- Drugs Ibrutinib (Primary) ; SNX 5422 (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Esanex
- 19 Oct 2017 According to an Esanex media release, first patient has been dosed.
- 10 Jun 2017 Biomarkers information updated
- 13 Feb 2017 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019.